

**CONTACT:** Bonnie Segal  
**PHONE:** 305-722-8444 ext. 2260  
**EMAIL:** [bsegal@segalinstitute.com](mailto:bsegal@segalinstitute.com)

**DR. STEVEN CHAVOUSTIE OF SEGAL INSTITUTE FOR CLINICAL RESEARCH  
LISTED AS AN AUTHOR ON RESEARCH PAPER**

**Dr. Steven Chavoustie co-authored a research paper on bacterial vaginosis**

**Miami, Florida – March 28<sup>th</sup>, 2017** – Segal Institute for Clinical Research’s Dr. Steven Chavoustie helped to author the research paper, “Experts explore the state of bacterial vaginosis and the unmet needs facing women and providers,” recently published in the International Journal of Gynecology & Obstetrics, the official publication of the International Federation of Gynecology and Obstetrics (FIGO).

Symbiomix, a women’s health biopharmaceutical company developing Solosec™ (secnidazole), a single-dose oral therapy for the treatment of bacterial vaginosis (BV), brought together nine women’s health leaders from across the USA on June 22, 2016. The meeting discussed the landscape of bacterial vaginosis, an infection that affects women around the world and is widely misdiagnosed, over-diagnosed and under-diagnosed.

Bacterial vaginosis is the most prevalent gynecologic infection in the USA. More than 21 million women are affected each year; while only 4 million women undergo treatment. Bacterial vaginosis is a condition that can have serious health implications, and if not treated properly, it can cause pre-term labor, pelvic inflammatory disease, and increased transmission of HIV and other sexually transmitted infections.

At the meeting, a consensus statement was reached. Health leaders agreed on greater awareness of bacterial vaginosis, emphasis on adopting point-of-care tests for proper diagnosis, and the importance of taking efficacy, tolerability, adherence and patient satisfaction into consideration when prescribing treatment for bacterial vaginosis.

“It is our hope that the consensus will help to bring this pressing women’s health issue to the forefront of provider and patient conversations,” commented Segal Institute’s board-certified gynecologist, Dr. Steven Chavoustie, MD, FACOG, CCRP. “Awareness and education are key factors to ensuring proper diagnosis and effective treatment, thereby preventing the serious health risks associated with BV.”

###

For more information on this release, contact Bonnie Segal at 305-722-8444 ext. 2260 or via email at [bsegal@segalinstitute.com](mailto:bsegal@segalinstitute.com)

## **About Segal Institute for Clinical Research**

Segal Institute for Clinical Research is a consortium of research sites specializing in psychiatric, neurological, addiction, medical and women's health clinical trials. A 60-plus staff of full-time Principal Investigators, Sub-Investigators, coordinators, research assistants and Master's- and Doctorate-level raters conducts clinical trials in outpatient, inpatient, nursing homes, and sleep laboratories. Segal Institute is currently conducting Phase I-IV research trials in 9 different sites in South Florida and South Carolina. Integral to Segal Institute's success is its centralized operations consisting of quality assurance and improvement managers, rater calibration specialists, recruiters, advertising coordinators, contract managers and call-center